Table 2.

Neurologic outcomes in MSRD patients post-COVID-19 (n = 111 patients).

	N (%)
No neurologic worsening	62/111 (55.8)
Unknown	6/111 (5.4)
Neurologic worsening	41/111 (36.9)
▒Relapse	▒2/41 (4.9)
▒Pseudorelapse	▒19/41 (46.3)
▒Worsening of preexisting MSRD symptoms	▒19/41 (46.3)
▒Other long term neurologic non MSRD symptoms	▒7/41 (17.1)
▒MRI changes	▒5/41 (12.2)

Legend: Table 2 shows neurologic outcomes in MSRD patients post-COVID-19. The two patients who passed away are not included in this table.